Clinical Trials
41 trialsStudy of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
National Institutes of Health Clinical Center (CC)
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
National Institutes of Health Clinical Center (CC)
MK-6482-043
Merck Sharp & Dohme LLC
MK-6482-015
Merck Sharp & Dohme LLC
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
ITHORinVHL
IRCCS San Raffaele
SJFAMILY
St. Jude Children's Research Hospital
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
National Institutes of Health Clinical Center (CC)
Institutional Registry of Rare Diseases
Hospital Italiano de Buenos Aires
Precision Medicine for Neurocutaneous Syndromes in Western China
West China Hospital
BELIEVE-VHL
AC Camargo Cancer Center
MK-6482-026
Merck Sharp & Dohme LLC
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
VHLimage
University Medical Center Groningen
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Peking University First Hospital
MyVHL
VHL Alliance
SoMuKT
IRCCS San Raffaele
PRO-HEB
Assistance Publique - Hôpitaux de Paris
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes
RenJi Hospital
A Study of BPI-452080 in Subjects With Solid Tumors
Betta Pharmaceuticals Co., Ltd.
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Von Hippel-Lindau Disease Genetic Epidemiology Study
National Institutes of Health Clinical Center (CC)
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Drivers of Hypoxia-induced Angiogenesis in Tumor Development
University of Copenhagen
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
University of Copenhagen
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
M.D. Anderson Cancer Center
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
National Institutes of Health Clinical Center (CC)
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Dartmouth-Hitchcock Medical Center
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
National Institutes of Health Clinical Center (CC)
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)